Form 4: Hookipa Pharma Director Jan van de Winkel Acquires 98,000 Stock Options

Director Jan van de Winkel acquired 98,000 stock options in Hookipa Pharma Inc. on June 17, 2024.

Summary

• Jan van de Winkel, a director of Hookipa Pharma Inc., acquired 98,000 stock options on June 17, 2024.
• The exercise price of these options is $0.71.
• The options vest on the earlier of June 17, 2025, or the date of the Issuer's next annual meeting of its stockholders.
• The options expire on June 17, 2034.
• Following the transaction, van de Winkel directly owns 98,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director, indicating confidence but not necessarily a major positive or negative event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates